Prevalence, Determinants, and Clinical Associations of High-Sensitivity Cardiac Troponin in Patients Attending Emergency Departments

Kuan Ken Lee, MD,a Ala Noaman, MD,a Amar Vaswani, MD,a Matthew Gibbins,a Megan Griffiths, BSc,a Andrew R. Chapman, MD,a Fiona Strachan, PhD,a Atul Anand, MD,a David A. McAllister, MD, MPH, PhD,b David E. Newby, MD, PhD,a Alasdair J. Gray, MD,c,d Nicholas L. Mills, MD, PhD,a Anoop S.V. Shah, MD, MPH, PhDa

aBHF Centre for Cardiovascular Science, University of Edinburgh, UK; bInstitute of Health and Wellbeing, University of Glasgow, UK; cDepartment of Emergency Medicine, Royal Infirmary of Edinburgh, UK; dEmergency Medicine Research Group Edinburgh (EMERGE), UK.

ABSTRACT

BACKGROUND: High-sensitivity cardiac troponin assays may improve the diagnosis of myocardial infarction but increase the detection of elevated cardiac troponin in patients without acute coronary syndrome.

METHODS: In a prospective cohort study, we evaluated the prevalence, determinants, and outcome of patients with elevated cardiac troponin attending the emergency department without suspected acute coronary syndrome. We measured high-sensitivity cardiac troponin I in 918 consecutive patients attending the emergency department without suspected acute coronary syndrome who had blood sampling performed by the attending clinician. Elevated high-sensitivity cardiac troponin I was defined as concentrations above the sex-specific 99th percentile threshold. Clinical demographics, physiological measures, and all-cause mortality at 1 year associated with elevated high-sensitivity cardiac troponin concentrations were recorded.

RESULTS: Elevated cardiac troponin concentration occurred in 114 (12.4%) patients, of whom 2 (0.2%), 3 (0.3%), and 109 (11.9%) were adjudicated as type 1 myocardial infarction, type 2 myocardial infarction, and myocardial injury, respectively. Elevated troponin concentrations were associated with increasing age, worsening renal function, multimorbidity, and adverse physiology. Across a total of 912 patient-years follow-up, cardiac troponin concentration was a strong predictor of death (hazard ratio [HR] 1.26 per 2-fold increase, 95% confidence interval [CI] 1.06 to 1.49) independent of age, sex, multimorbidity, and adverse physiology.

CONCLUSIONS: High-sensitivity cardiac troponin concentrations were elevated in 1 in 8 consecutive patients without suspected acute coronary syndrome attending the emergency department and were associated with increasing age, multimorbidity, adverse physiology, and death. Elevated cardiac troponin in unselected patients predominantly reflects myocardial injury rather than myocardial infarction.

KEY WORDS: Acute coronary syndrome; Diagnosis; High-sensitivity cardiac troponin; Myocardial infarction; Myocardial injury

BACKGROUND

Although cardiac troponin is integral to the diagnosis of myocardial infarction,1 the approach to testing varies markedly across different healthcare systems.2-4 In some centers, cardiac troponin is used as a screening test, irrespective of the clinical presentation.3 In a representative sample of patients attending emergency departments in the United States, cardiac troponin was measured in 1 in 5 patients.5 Moreover, in more than half of those who were subsequently hospitalized, one-third of patients did not have any cardiac symptoms.5
We recently assessed the variation in patient selection for high-sensitivity troponin testing between emergency departments and its impact on the diagnosis of type 1 myocardial infarction.\(^5\) Compared to the United Kingdom, cardiac troponin testing was performed more widely in the United States, resulting in a much lower prevalence (4.2% vs 14.5%) and positive predictive value (16.4% vs 59.7%) for type 1 myocardial infarction in those patients tested.\(^5\) These findings highlight the importance of patient selection to optimize the diagnostic utility of cardiac troponin testing for type 1 myocardial infarction.\(^5\)

High-sensitivity cardiac troponin assays have been widely implemented in many countries and have improved the diagnosis of myocardial infarction\(^1,7\) and risk stratification in patients with suspected acute coronary syndrome.\(^7\) However, the high-sensitivity test also increases the detection of elevated cardiac troponin in many cardiac and non-cardiac conditions that are unrelated to acute coronary syndrome.\(^8-10\) As such, the introduction of a high-sensitivity cardiac troponin assay may contribute to diagnostic uncertainty, particularly in healthcare settings where indiscriminate testing is high.\(^2,5\)

Here, we aim to evaluate the prevalence of elevated high-sensitivity cardiac troponin concentrations in consecutive patients without suspected acute coronary syndrome in emergency department and describe the determinants and clinical associations of high-sensitivity cardiac troponin concentrations.

**METHODS**

**Study Population**

We prospectively identified consecutive patients presenting to the Emergency Department at the Royal Infirmary of Edinburgh, Scotland, between July 5 and 16, 2013. The Royal Infirmary of Edinburgh Emergency Department serves a population of more than 1 million across the south east of Scotland. It is an adult tertiary emergency department, serving as regional referral center for trauma, surgery, and cardiology, assessing approximately 120,000 patients annually.

All patients without suspected acute coronary syndrome in whom the attending clinician performed blood sampling at presentation and did not request a cardiac troponin test were eligible for inclusion in this analysis (Supplementary Figure 1). Excess serum from blood samples were used to measure high-sensitivity cardiac troponin I. These results were not reported to the attending clinician to guide clinical care. Patients who had a previous admission during the study period, or in whom there was insufficient sample volume for analysis, were excluded. This study was performed with approval from the National Health Service Research Scotland BioResource and Tissue Governance Unit in accordance with the Declaration of Helsinki. Surplus material was acellular, individual consent from each patient was not sought. However, to comply with our governance policy, we used an encrypted identification number for each individual troponin result measured on excess serum to ensure that they were never linked to patient identifiers. We have employed a similar approach for previous clinical trials and cohort studies conducted in this manner.\(^6-8,11-12\)

**Troponin Assay**

Excess serum was analyzed using the ARCHITECT\(_{\text{STAT}}\) high-sensitive troponin I assay (Abbott Laboratories, Abbott Park, IL, USA). This assay has a limit of detection of 1.2 ng/L and the inter-assay CV <10% at 4.7 ng/L. The 99th percentile upper reference limit (URL) is 34 ng/L in men and 16 ng/L in women.\(^12,13\)

**Clinical Characteristics**

Baseline clinical characteristics and investigations were obtained from a standardized electronic patient record (TrakCare, InterSystems Corporation, Cambridge, MA, USA) as previously described.\(^3,12,14\) These included medical history, cardiovascular risk factors, presenting symptoms, medication use, and electrocardiographic abnormalities. Hyperlipidemia and hypertension were defined as a documented history of the condition or by the respective use of lipid-lowering or antihypertensive medications. The National Early Warning Score (NEWS) was calculated for patients incorporating six simple physiological variables (ie pulse rate, blood pressure, temperature, oxygen saturations, level of consciousness, and respiratory rate measured at admission; Supplementary Table 1).\(^15\)

**Classification of Myocardial Injury and Myocardial Infarction**

Elevated cardiac troponin concentration was defined using sex-specific thresholds at the 99th percentile URL.\(^1,7,16\)

Two cardiologists reviewed all clinical information independently, including noninvasive and invasive investigations and outcomes from admission to 30 days as described...
Patients with elevated cardiac troponin were classified according to the universal definition of myocardial infarction. Type 1 myocardial infarction was defined in which myocardial necrosis occurred in the context of a presentation with symptoms suggestive of an acute coronary syndrome or evidence of myocardial ischemia on the electrocardiogram. Patients with myocardial necrosis and symptoms or signs of myocardial ischemia as a result of increased oxygen demand or decreased supply (eg tachyarrhythmia, hypotension, or anemia) due to an alternative diagnosis were classified as type 2 myocardial infarction. Myocardial injury was defined as elevated cardiac troponin concentration without signs or symptoms of myocardial ischemia. A third adjudicator resolved any discrepancies in adjudication through in-depth review of source documents.

Clinical Outcomes
Death from any cause was identified from regional and national registries including the General Register of Scotland, allowing capture of all deaths in the hospital and in the community, ensuring complete follow-up in all patients. Patients who were not residents of Scotland were censored at the time of discharge.

Statistical Analysis
Patients were divided into four groups a priori: those patients with cardiac troponin concentrations >99th percentile URL (men >34 ng/L and women >16 ng/L; group 4) and the remaining patients separated into three equal ter-
tiles (groups 1-3). The distribution of cardiac troponin dif-
dered in men and women (Supplementary Figure 2), and therefore, they were grouped separately. Summary statistics were derived for all patients stratified by these four groups. Continuous variables were compared using parametric and nonparametric tests as appropriate.

We calculated the prevalence of elevated cardiac tropo-
nin across the whole population and stratified by age, sex, known ischemic heart disease, renal function, and comor-
bidity (eg hypertension, ischemic heart disease, peripheral vascular disease, diabetes mellitus, and cerebrovascular dis-
ease). Where the prevalence was close to 0%, we calculated the 95% confidence interval (CI) using a Bayesian approach by sampling from a binomial likelihood with a noninformative Jeffreys prior ($\beta$-distribution shape parameters both equal to 0.5).

Factors associated with elevated cardiac troponin concentrations were modeled using logistic regression with adjustment for age, sex, renal function, multimorbidity (eg hypertension, diabetes mellitus, ischemic heart disease, cerebrovascular disease, or peripheral vascular disease) and NEWS. Occurrence of death was modelled using a Cox-
proportional hazards regression with troponin (natural log) as the explanatory variable both as a single variable and after adjusting for age, sex, renal function, and NEWS. We examined the linearity of the association between troponin concentration and risk of death using Cox-proportional regression models with smoothing splines for high-sensitiv-
ity cardiac troponin concentrations and 4 degrees of free-
dom. Cox-regression models were constructed and evaluated for the proportional hazards assumption. Analyses were performed in R Version 3.5.1 Statistical signifi-
cance was taken as a two-sided P < 0.05.

RESULTS
Study Population
There were 3619 attendances to the Emergency Department across the study period, and blood samples were obtained as part of routine clinical care in 1103 (Supplementary Figure 1). Prior inclusion in the study or insufficient blood sample for analysis excluded 49 patients. The attending clinician requested cardiac troponin in 12.9% (n=136) of all patients who had blood drawn. Patients who had a troponin test requested were more likely to have presented to the emergency department with chest pain (79.4% vs 8.3%, P-value <0.001), have cardiac risk factors, and past medical history of ischemic heart disease (Supplementary Table 2). These patients (n = 136) were excluded, resulting in a final study population of 918 patients (Supplementary Figure 1).

Prevalence of Elevated Cardiac Troponin Concentration
The prevalence of elevated cardiac troponin was 12.4% (n=114/918). Two (0.2%) and 3 (0.3%) patients with ele-
ved cardiac troponin concentrations were adjudicated as hav-
ing had type 1 and type 2 myocardial infarction, respec-
tively, with the remaining 109 patients adjudicated as hav-
ing myocardial injury (11.9%) (Figure 1, Supplementary Table 2).

Determinants of Elevated Cardiac Troponin Concentration
Patients with elevated cardiac troponin (group 4) were older (78 ± 17 vs 34 ± 13 years, P < 0.001) and more likely to have comorbid conditions than those with the lowest car-
diac troponin concentrations (group 1) (Table 1). Patients with elevated cardiac troponin were also more likely to have adverse physiology (medium or high-risk NEWS, 19.5% vs 2.4%, P <0.001), lower hemoglobin concentra-
tions (12.1±2.4 vs 13.7±1.6 g/dL, P<0.001), and higher creatinine concentrations (1.30±1.00 vs 0.80±0.16 mg/ dL).

On logistic regression modeling, both age (model 1: odds ratio [OR] 2.13, 95% CI 1.78 to 2.62 per 10-year increment) and comorbidity (model 2: OR 10.11, 95% CI 4.3 to 23.81 for 3 or more comorbidities compared to none) were strongly associated with elevated cardiac troponin after adjusting for sex, renal function, and NEWS (Table 2). When adjusting for both age and comorbidity, age remained a powerful determinant of elevated cardiac
troponin (model 3: OR 2.07, 95% CI 1.70 to 2.59 per 10 years increment, P<0.001).

Outcomes of Patients with Elevated Cardiac Troponin Concentration

Most patients with elevated cardiac troponin were admitted into hospital (96/114, 84.2%). Patients with elevated cardiac troponin (group 4) were more likely to have died at 30 days and 1 year than those with the lowest cardiac troponin concentrations (group 1) (19.3% vs 0.6% at 30 days, P-value (log-rank) <0.001 and 37.7% vs 1.9% at 1 year, P<0.001; Table 1 and Figure 2A). With time to event analysis, across a total of 912 patient-years of follow-up, cardiac troponin concentration was a strong predictor of death (hazard ratio [HR] 1.62, 95% CI 1.50 to 1.75, p<0.001 for every doubling of troponin concentration; Figure 2A and 2B). This association attenuated after adjusting for age, sex, multimorbidity, adverse physiology, and renal function (HR 1.26, 95% CI 1.06 to 1.49, P=0.003 for every doubling of troponin concentration). There was a near linear relationship between troponin concentration at presentation and risk of death (Figure 2B). The proportional hazards assumption for the Cox model was met (P=0.664).

DISCUSSION

Given the increasing use of high-sensitivity cardiac troponin assays in clinical practice and the potential diagnostic challenges that elevated troponin concentrations may pose, we evaluated the prevalence and factors associated with an elevated cardiac troponin concentration in consecutive patients to the Emergency Department who did not have suspected acute coronary syndrome in whom the attending clinician performed blood sampling. We make several important observations. First, in our center, approximately 1 in every 8 patients without suspected acute coronary syndrome who underwent blood sampling had an elevated cardiac troponin concentration. Nearly half of all patients older than the age of 80 or with greater than 3 comorbid conditions had an elevated cardiac troponin concentration. Third, elevated cardiac troponin concentration was associated with adverse physiology at presentation. Age, serum creatinine, hemodynamic compromise, and hypoxia were strong predictors of an elevated cardiac troponin. Finally, most patients with elevated cardiac troponin were admitted into hospital, and every doubling in troponin concentration was associated with mortality independent of age, sex, renal function, and adverse physiology.

To our knowledge, this is the first study to evaluate the determinants of elevated cardiac troponin in consecutive patients Emergency Department patients without suspected acute coronary syndrome with several important strengths in the study design. We used a consecutive patient population attending the Emergency Department who underwent blood sampling to minimize selection bias. In comparison, previous studies have evaluated the frequency of type 2 myocardial infarction and myocardial injury only in patients who had troponin testing clinically requested.10,18 We also used a clinically available high-sensitivity troponin I assay with excellent precision to measure cardiac troponin. This assay has superior analytical performance compared to previous generations of cardiac troponin assays with a limit of detection 10-fold lower than contemporary sensitive assays.19,20 Finally, to ensure robust follow-up of patients, we used comprehensive local and national death registries.8,12

In our study, elevated cardiac troponin concentration was common in patients without suspected acute coronary syndrome in whom troponin testing was not requested by the attending clinician. Age and admission physiology were the strongest independent factors associated with elevated troponin concentrations. Although elevated cardiac troponins are specific for indicating damage to the myocardium, they are not specific for the etiology of injury. As such, many acute and chronic pathological conditions are associated with elevated cardiac troponins.20,21
Table 1  Baseline Characteristics of Patients Stratified by High-Sensitivity Cardiac Troponin Concentration

| Range of troponin concentration, ng/L | All (n = 918) | Group 1 (n = 316) | Group 2 (n = 236) | Group 3 (n = 252) | Group 4 (n = 114) | P-value |
|--------------------------------------|---------------|-------------------|-------------------|-------------------|-------------------|---------|
| Males                                |               |                   |                   |                   |                   |         |
| Age (years)                          | 53.0 ± 23.0   | 34.0 ± 13.1       | 50.5 ± 17.9       | 67.9 ± 18.2       | 77.6 ± 16.5       | <0.001  |
| Male sex                             | 156 (49.4)    | 101 (42.8)        | 127 (50.4)        | 42 (36.8)         | 0.043             |         |
| Past medical history                 |               |                   |                   |                   |                   |         |
| Ischemic heart disease               | 127 (14.0)    | 9 (2.9)           | 18 (7.7)          | 62 (24.9)         | 38 (33.3)         | <0.001  |
| Myocardial infarction                | 61 (6.7)      | 5 (1.6)           | 7 (3.0)           | 31 (12.4)         | 18 (15.8)         | <0.001  |
| Systolic BP (mm Hg)                  | 130.5 ± 22.3  | 127.0 ± 16.7      | 134.9 ± 25.5      | 130.1 ± 26.8      | 0.003             |         |
| Oxygen saturations (%)               | 96.8 ± 3.0    | 97.9 ± 1.8        | 97.1 ± 2.1        | 96.0 ± 3.3        | 95.1 ± 4.7        | <0.001  |
| On oxygen                            | 52 (6.3)      | 4 (1.5)           | 6 (2.8)           | 19 (8.3)          | 23 (21.9)         | <0.001  |
| Hematology and biochemistry          |               |                   |                   |                   |                   |         |
| Hemoglobin (g/dL)                    | 13.3 ± 2.0    | 13.9 ± 1.5        | 13.5 ± 1.7        | 12.9 ± 2.1        | 12.1 ± 2.4        | <0.001  |
| Creatinine (mg/dL)                   | 0.96 ± 0.74   | 0.80 ± 0.16       | 0.88 ± 0.78       | 1.07 ± 0.90       | 1.30 ± 1.00       | <0.001  |
| Urea (mg/dL)                         | 5.9 ± 3.7     | 4.4 ± 1.5         | 5.1 ± 2.4         | 7.0 ± 4.1         | 9.7 ± 5.5         | <0.001  |
| Admission drugs                      |               |                   |                   |                   |                   |         |
| Aspirin                              | 130 (14.5)    | 7 (2.3)           | 19 (8.2)          | 66 (27.0)         | 38 (33.9)         | <0.001  |
| Clopidogrel                          | 62 (6.9)      | 5 (1.6)           | 10 (4.3)          | 33 (13.5)         | 14 (12.5)         | <0.001  |
| Beta-blockers                        | 109 (12.1)    | 9 (2.9)           | 24 (10.3)         | 45 (18.4)         | 31 (27.7)         | <0.001  |
| ACE-I/ARB                            | 143 (15.9)    | 9 (2.9)           | 34 (14.7)         | 63 (25.8)         | 37 (33.0)         | <0.001  |
| Statin                               | 192 (21.4)    | 13 (4.2)          | 43 (18.5)         | 91 (37.3)         | 45 (40.2)         | <0.001  |
| Warfarin                             | 35 (3.9)      | 1 (0.3)           | 7 (3.0)           | 16 (6.6)          | 11 (9.9)          | <0.001  |
| PPI                                  | 184 (20.5)    | 28 (9.0)          | 52 (22.4)         | 65 (26.6)         | 39 (34.8)         | <0.001  |

PT value
unsurprisingly, elevated cardiac troponin concentrations are common in a critical-care setting, and likely to be secondary to multiple mechanisms.22 Potential mechanisms of injury include direct toxicity, hemodynamic compromise, and, in some cases, increased thrombogenicity precipitating a type 1 myocardial infarction. Myocardial oxygen supply-demand imbalance is a major factor in the critically ill, and both hypotension and increased metabolic demand are correlated with troponin concentrations.23 In addition, elevated cardiac troponin are also associated with inflammatory cytokines that may cause direct myocardial toxicity.24

So, what information do cardiac troponin levels convey in patients attending the emergency department? There are many cardiac and noncardiac conditions unrelated to type 1 myocardial infarction that may result in elevated troponin concentrations. The universal definition of myocardial infarction acknowledges this diversity by classifying elevated troponin levels in such instances as either type 2 myocardial infarction or myocardial injury.16 Our analysis confirms previous studies demonstrating close associations among troponin concentrations, acute illness severity, and increased risk of death.8,22 These associations remain robust and independent of known important confounders including age, sex, multimorbidity, renal function, and adverse physiological measures.

Our study has several broad clinical implications when adopting high-sensitivity assays. First, the prevalence of elevated high-sensitivity cardiac troponin is high in patients attending the emergency department without suspected acute coronary syndrome. High-sensitivity assays were introduced into clinical practice in Australasia, Canada, and Europe in 2010, yet the first high-sensitivity assay has only recently received approval from the U.S. Food and Drug Administration for use in the United States.20,28 Although lowering the diagnostic threshold of cardiac troponin using more sensitive assays does not result in an increased number of tests per se, it does result in an increased proportion of “positive” results and an increased detection of nonacute coronary syndrome pathologies.2,29 Indiscriminate troponin testing in patients without signs or symptoms consistent with acute coronary syndrome should be discouraged because it is likely to increase the challenges involved in interpreting troponin test results for the attending clinician. Second, although troponin elevations detected with these novel assays identify patients at risk of death, there is currently no evidence that these patients with an elevated

Table 1

| Outcomes                  | All (n = 918) | Group 1 (n = 316) | Group 2 (n = 236) | Group 3 (n = 252) | Group 4 (n = 114) | P-value |
|---------------------------|--------------|-------------------|-------------------|-------------------|-----------------|---------|
| Admitted to hospital      | 512 (56.2)   | 128 (41.0)        | 119 (50.6)        | 169 (67.6)        | 96 (84.2)       | <0.001  |
| 30-day death              | 32 (3.5)     | 2 (0.6)           | 1 (0.4)           | 7 (2.8)           | 22 (19.3)       | <0.001  |
| 1-year death              | 102 (11.1)   | 6 (1.9)           | 13 (5.5)          | 40 (15.9)         | 43 (37.7)       | <0.001  |

Values are n (%) or mean ± SD.

ACE-I/ARB = angiotensin converting enzyme inhibitor/angiotensin receptor blocker; BP = blood pressure; bpm = breaths/beats per minute; CABG = coronary artery bypass grafting; ECG = electrocardiogram; LBBB = left bundle branch block; NEWS = National Early Warning Score; PCI = percutaneous coronary intervention; PPI = proton pump inhibitor; RBBB = right bundle branch block.

Table 2 Logistic Regression Models for Determinants of Elevated Cardiac Troponin in Unselected Patients Attending the Emergency Department

| Variable          | Model 1, OR (95% CI) | Model 2, OR (95% CI) | Model 3, OR (95% CI) |
|-------------------|----------------------|----------------------|----------------------|
| Age, per 10 years | 2.13 (1.78 – 2.62)*  | -                    | 2.07 (1.70 – 2.58)*  |
| Creatinine, per 0.11 mg/dL | 1.03 (1.00 – 1.07) | 1.03 (1.00 – 1.06) | 1.03 (1.00 – 1.06) |
| Sex (Male)        | 0.56 (0.31 – 0.91)  | 0.38 (0.21 – 0.67)*  | 0.52 (0.27 – 0.94)  |
| NEWS, per 1 unit  | 1.55 (1.33 – 1.83)*  | 1.57 (1.36 – 1.83)*  | 1.56 (1.33 – 1.84)*  |
| Comorbidity       | 1                    | 1                    | 1                    |
| None (referent)   | -                    | 1                    | 1                    |
| 1                 | 4.59 (2.37 – 8.99)*  | 1.24 (0.58 – 2.63)  |
| 2                 | 4.49 (2.07 – 9.62)*  | 0.95 (0.40 – 2.25)  |
| Over 3            | 10.11 (4.3 – 23.81)* | 2.16 (0.85 – 5.47)  |
| AIC (model fit)   | 325                  | 386                  | 324                  |

AIC = Akaike Information Criterion; CI, confidence interval; NEWS = National Early Warning Score; OR = odds ratio.

*p value <0.001.

| p value <0.05. |
Figure 2  (A) Cumulative incidence for all-cause mortality in patients in whom cardiac troponin was not requested by the attending clinician, stratified by cardiac troponin concentration at presentation. (B) Association between cardiac troponin concentration and hazard ratio for death. Estimates obtained from a Cox regression model with penalized smoothing splines and adjusted for age, sex, and renal function. Rug plot shows density of data for given value of cardiac troponin.
troponin who do not have a diagnosis of type 1 myocardial infarction would benefit from any additional therapy. Third, elevated troponin concentrations reflect cardiac damage analogous to creatinine for acute kidney injury or hypoxia in the context of acute lung injury. As such, elevated cardiac troponin concentrations not resulting from a primary coronary pathology (ie type 1 myocardial infarction) identify patients with an acute illness and adverse physiology. In our cohort, most patients with undisclosed elevated cardiac troponin concentration were admitted to hospital. Two patients (0.2%) were adjudicated as type 1 myocardial infarction of whom one patient was a 94-year-old man diagnosed as a late presentation myocardial infarction clinically and received palliative care in the hospital, highlighting that the attending clinicians were good at discriminating those patients who required further in-patient investigation and care.

**Limitations**

There were several limitations in our study. Our cohort originated from a single center. However, our Emergency Department is in a large tertiary center providing acute medical care to the southeast of Scotland. We would not therefore envisage our patient population to be different from other Emergency Departments and consider our results and interpretation generalizable. However, we acknowledge that this study was conducted during the summer, and therefore, the study population may not be representative of the patient population presenting to Emergency Departments during the winter months. We also did not have serial troponin concentrations and are not able to comment on the whether there was an acute rise or fall in troponin concentrations. As such, our classification of the myocardial injury is based on a single baseline sample and may have underestimated the prevalence of myocardial infarction as a result of misclassification. Moreover, we only measured troponin concentration in patients who had blood sampling performed by the attending clinician. Although this might have introduced some confounding by indication, we believe this ensured that our study is representative of the broad population of patients presenting to the Emergency Department who were sufficiently unwell to require blood testing. It is in this group of patients in which diagnostic uncertainty may arise should troponin testing is requested indiscriminately.

**CONCLUSION**

This is the first study that has evaluated high-sensitivity cardiac troponin concentrations in consecutive patients attending an Emergency Department without suspected acute coronary syndrome, in whom blood sampling was undertaken by the attending physician. Our analysis shows that elevated cardiac troponin concentrations are common in patients without suspected acute coronary syndrome. Troponin concentration is strongly associated with age, comorbidities, adverse physiology at presentation, and subsequent poorer outcomes. As high-sensitivity cardiac troponin assays are adopted more widely, an improved understanding of the prevalence, determinants, and clinical associations of cardiac troponin in patients without acute coronary syndrome is required to ensure that test results are interpreted correctly and the subsequent clinical management is appropriate.

**References**

1. Shah ASV, Newby DE, Mills NL. High sensitivity cardiac troponin in patients with chest pain. *BMJ*. 2013;347:f4222.
2. Melanson SE, Conrad MJ, Mosammabarat N, Jarolim P. Implementation of a highly sensitive cardiac troponin I assay: test volumes, positivity rates and interpretation of results. *Clin Chim Acta*. 2008;395(1-2):57–61.
3. Jairam S, Jones P, Samaraie L, Chataline A, Davidson J, Stewart R. Clinical diagnosis and outcomes for Troponin T ‘positive’ patients assessed by a high sensitivity compared with a 4th generation assay. *Emerg Med Australas*. 2011;23(4):490–501.
4. Yiadam MY, Jarolim P, Jenkins C, Melanson SE, Conrad M, Kosowsky JM. Diagnostic implications of an elevated troponin in the emergency department. *Dis Markers*. 2015;2015:157812.
5. Makam AN, Nguyen OK. Use of cardiac biomarker testing in the emergency department. *JAMA Intern Med*. 2015;175(1):67–75.
6. Shah ASV, Sandoval Y, Noaman A, et al. Patient selection for high sensitivity cardiac troponin testing and diagnosis of myocardial infarction: prospective cohort study. *BMJ*. 2017;359:j4788.
7. Shah ASV, Anand A, Sandoval Y, et al. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. *Lancet*. 2015;386(10012):2481–2488.
8. Shah ASV, McAllister DA, Mills R, et al. Sensitive troponin assay and the classification of myocardial infarction. *Am J Med*. 2015;128(5):493-501.e3.
9. Newby LK, Jesse RL, Babb JD, et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. *J Am Coll Cardiol*. 2012;60(23):2427–2463.
10. Chapman AR, Shah ASV, Lee KK, et al. Long term outcomes in patients with type 2 myocardial infarction and myocardial injury. *Circulation*. 2018;137(12):1236–1245.
11. Shah ASV, Anand A, Strachan FE, et al. High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. *The Lancet*. 2018;392(10151):919–928.
12. Shah ASV, Griffiths M, Lee KK, et al. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. *BMJ*. 2015;350:g7873.
13. Shah ASV, Ferry AV, Mills NL. Cardiac biomarkers and the diagnosis of myocardial infarction in women. *Curr Cardiol Rep*. 2017;19(5):40.
14. Mills NL, Churchhouse AMD, Lee KK, et al. Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. *JAMA*. 2011;305(12):1210–1216.
15. Royal College of Physicians. *National early warning score (NEWS): standardising the assessment of acute illness severity in the NHS*. London: Royal College of Physicians; 2012.
16. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. *Circulation*. 2012;126(16):2020–2035.
17. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the West of Scotland Coronary Prevention Study. *N Engl J Med*. 2007;357(15):1477–1486.
18. Saaby L, Poulsen TS, Diederichsen AC, et al. Mortality rate in type 2 myocardial infarction: observations from an unselected hospital cohort. *Am J Med*. 2014;127(4):295–302.
19. Apple FS. A new season for cardiac troponin assays: it’s time to keep a scorecard. *Clin Chem*. 2009;55(7):1303–1306.
20. Korley FK, Jaffe AS. Preparing the United States for high-sensitivity cardiac troponin assays. *J Am Coll Cardiol*. 2013;61(17):1753–1758.
21. Sherwood MW, Kristin Newby L. High-sensitivity troponin assays: evidence, indications, and reasonable use. *J Am Heart Assoc*. 2014;3(1):e000403.
22. Lim W, Whitlock R, Khera V, et al. Etiology of troponin elevation in critically ill patients. *J Crit Care*. 2010;25(2):322–328.
23. Arlati S, Brenna S, Prencipe L, et al. Myocardial necrosis in ICU patients with acute non-cardiac disease: a prospective study. *Intensive Care Med*. 2000;26(1):31–37.
24. Werdan K, Oelke A, Hettwer S, et al. Septic cardiomyopathy: hemodynamic quantification, occurrence, and prognostic implications. *Clin Res Cardiol*. 2011;100(8):661–668.
25. Bouhemad B, Nicolas-Robin A, Arbelot C, Arthaud M, Feger F, Rouby JJ. Isolated and reversible impairment of ventricular relaxation in patients with septic shock. *Crit Care Med*. 2008;36(3):766–774.
26. Witthaut R, Busch C, Fraunberger P, et al. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. *Intensive Care Med*. 2003;29(10):1696–1702.
27. Ammann P, Maggiorini M, Bertel O, et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. *J Am Coll Cardiol*. 2003;41(11):2004–2009.
28. 510(k) substantial equivalence determination decision summary assay only template. In: *Administration US FaD*, ed2017.
29. Mills NL, Lee KK, McAllister DA, et al. Implications of lowering threshold of plasma troponin concentration in diagnosis of myocardial infarction: cohort study. *BMJ*. 2012;344:e1533.
Supplementary Table 1  Parameters and Scoring System of the National Early Warning Score (NEWS)

| Points | 3    | 2    | 1    | 0    | 1    | 2    | 3    |
|--------|------|------|------|------|------|------|------|
| Respiratory rate, breaths per minute | ≤8   | 9 to 11 | 12 to 20 | 21 to 24 | ≥25 | |
| Oxygen saturations, % | ≤91  | 92 to 93 | 94 to 95 | ≥96 | 96 | 96 | 96 |
| Any supplemental oxygen | No   | Yes | No | No | No | No | No |
| Temperature, °C | ≤35.0 | 36.1 to 38.0 | 39.1 | 39.1 | 39.1 | 39.1 | 39.1 |
| Systolic blood pressure, mmHg | ≤90  | 91 to 100 | 101 to 110 | 111 to 219 | 219 | 219 | 219 |
| Heart rate, beats per minute | ≤40  | 41 to 50 | 51 to 90 | 91 to 110 | 111 to 130 | 130 | 130 |
| Consciousness | Voice, Pain or Unresponsive | Voice, Pain or Unresponsive | Voice, Pain or Unresponsive | Voice, Pain or Unresponsive | Voice, Pain or Unresponsive | Voice, Pain or Unresponsive | Voice, Pain or Unresponsive |

Supplementary Figure 1  Flow diagram of the study population of unselected patients attending the Emergency Department
### Supplementary Table 2  Baseline Characteristics of Consecutive Patients in the Emergency Department With and Without Cardiac Troponin Testing Requested by the Attending Clinician

|                              | Troponin requested by clinician |
|------------------------------|--------------------------------|
|                              | All \((n=1,054)\) | No \((n=918)\) | Yes \((n=136)\) | P-value |
| Male sex                     | 505 (47.9) | 426 (46.4) | 79 (58.1) | 0.014  |
| Age (years)                  | 54.5 ± 22.6 | 53.0 ± 23.0 | 64.9 ± 16.4 | <0.001 |
| Elevated cardiac troponin*   | 144 (13.7) | 114 (12.4) | 30 (22.1) | <0.001 |
| Presenting complaint         |                  |              |              |        |
| Chest pain, n (%)            | 183 (17.6) | 75 (8.3) | 108 (79.4) | <0.001 |
| Abdominal pain, n (%)        | 160 (15.2) | 156 (17.0) | 4 (2.9) | <0.001 |
| Fall/collapse, n (%)         | 158 (15.0) | 151 (16.4) | 7 (5.1) | 0.001  |
| Dyspnea, n (%)               | 57 (5.4) | 51 (5.6) | 6 (4.4) | 0.728  |
| Confusion, n (%)             | 18 (1.7) | 17 (1.9) | 1 (0.7) | 0.56   |
| Dizziness, n (%)             | 14 (1.3) | 13 (1.4) | 1 (0.7) | 0.806  |
| Other, n (%)                 | 464 (44.0) | 455 (49.6) | 9 (6.6) | <0.001 |

#### Risk factors

|                  | All \((n=1,054)\) | No \((n=918)\) | Yes \((n=136)\) | P-value |
|------------------|-------------------|---------------|----------------|---------|
| Smoker           | 299 (33.1) | 258 (33.2) | 41 (32.5) | 0.957   |
| Ex-smoker        | 154 (17.1) | 119 (15.3) | 35 (27.8) | 0.001   |
| Hypertension     | 337 (32.4) | 257 (28.4) | 80 (59.3) | <0.001 |
| Hyperlipidemia   | 299 (28.7) | 230 (25.4) | 69 (51.5) | <0.001 |
| Family history   | 26 (2.5) | 9 (1.0) | 17 (12.7) | <0.001 |

#### Past medical history

|                          | All \((n=1,054)\) | No \((n=918)\) | Yes \((n=136)\) | P-value |
|--------------------------|-------------------|---------------|----------------|---------|
| Ischemic heart disease   | 193 (18.5) | 127 (14.0) | 66 (48.9) | <0.001 |
| Myocardial infarction    | 109 (10.5) | 61 (6.7) | 48 (35.6) | <0.001 |
| Cerebrovascular disease  | 99 (9.5) | 83 (9.2) | 16 (11.9) | 0.403   |
| Peripheral vascular disease | 50 (4.8) | 43 (4.7) | 7 (5.2) | 0.992   |
|                                        | All (n=1,054) | No (n=918) | Yes (n=136) | P-value |
|----------------------------------------|--------------|------------|-------------|---------|
| **Diabetes mellitus**                   | 106 (10.1)   | 81 (8.9)   | 25 (18.5)   | 0.001   |
| **Previous revascularisation**         |              |            |             |         |
| PCI                                    | 52 (5.0)     | 28 (3.1)   | 24 (17.8)   | <0.001  |
| CABG                                   | 32 (3.1)     | 19 (2.1)   | 13 (9.6)    | <0.001  |
| **Admission physiological parameters** |              |            |             |         |
| Respiratory rate (bpm)                 | 18.2 ± 4.2   | 18.3 ± 4.3 | 17.8 ± 3.4  | 0.253   |
| Temperature (°C)                       | 36.9 ± 0.9   | 36.9 ± 0.9 | 36.6 ± 0.6  | 0.003   |
| Pulse rate (bpm)                       | 86.9 ± 22.3  | 87.7 ± 22.1| 81.8 ± 23.0 | 0.008   |
| Systolic BP (mmHg)                     | 130.5 ± 22.2 | 130.5 ± 22.3| 130.8 ± 21.9| 0.887   |
| Oxygen saturations (%)                 | 96.8 ± 2.9   | 96.8 ± 3.0 | 96.7 ± 2.2  | 0.7     |
| On oxygen                              | 62 (6.6)     | 52 (6.3)   | 10 (8.1)    | 0.598   |
| **Consciousness**                      |              |            |             | 0.515   |
| Alert                                  | 1014 (96.8)  | 880 (96.6) | 134 (98.5)  |         |
| Verbal                                 | 14 (1.3)     | 14 (1.5)   | 0 (0.0)     |         |
| Pain                                   | 8 (0.8)      | 7 (0.8)    | 1 (0.7)     |         |
| Unresponsive                           | 11 (1.1)     | 10 (1.1)   | 1 (0.7)     |         |
| **Killip class**                       |              |            |             | 0.012   |
| 0                                      | 6 (0.6)      | 6 (0.7)    | 0 (0.0)     |         |
| 1                                      | 930 (89.7)   | 819 (80.8) | 111 (82.2)  |         |
| 2                                      | 85 (8.2)     | 65 (7.2)   | 20 (14.8)   |         |
| 3                                      | 15 (1.4)     | 11 (1.2)   | 4 (3.0)     |         |
| 4                                      | 1 (0.1)      | 1 (0.1)    | 0 (0.0)     |         |
| **Hematology and biochemistry**        |              |            |             |         |
| Hemoglobin (g/dL)                      | 13.3 ± 1.9   | 13.3 ± 2.0 | 13.2 ± 1.7  | 0.590   |
| Creatinine (mg/dL)                     | 0.97 ± 0.72  | 0.96 ± 0.74| 1.04 ± 0.58 | 0.207   |
| Urea (mg/dL)                           | 6.1 ± 3.7    | 5.9 ± 3.7  | 6.8 ± 3.8   | 0.017   |
| Troponin I (ng/L)                      | 3.0 [2.0, 10.0]| 3.0 [2.0, 9.0]| 5.0 [3.0, 19.5]| <0.001 |
| **Admission drugs**                    |              |            |             |         |
| Aspirin                                | 180 (17.5)   | 130 (14.5) | 50 (37.6)   | <0.001  |
| Clopidogrel                            | 81 (7.9)     | 62 (6.9)   | 19 (14.3)   | 0.005   |
| Beta-blockers                          | 149 (14.5)   | 109 (12.1) | 40 (30.1)   | <0.001  |
| ACE-I/ARB                              | 189 (18.3)   | 143 (15.9) | 46 (34.6)   | <0.001  |
| Statin                                 | 249 (24.2)   | 192 (21.4) | 57 (42.9)   | <0.001  |
| Warfarin                               | 44 (4.3)     | 35 (3.9)   | 9 (6.8)     | 0.195   |
| PPI                                    | 233 (22.6)   | 184 (20.5) | 49 (36.8)   | <0.001  |
| **Admission electrocardiogram**        |              |            |             |         |
| ST elevation                           | 13 (2.0)     | 5 (1.0)    | 8 (6.0)     | 0.001   |
| ST depression                          | 21 (3.2)     | 9 (1.7)    | 12 (9.0)    | <0.001  |
| T-wave inversion                       | 58 (8.9)     | 34 (6.5)   | 24 (18.0)   | <0.001  |
| New LBBB                               | 11 (1.7)     | 5 (1.0)    | 6 (4.5)     | 0.014   |
| Old LBBB                               | 17 (2.6)     | 13 (2.5)   | 4 (3.0)     | 0.982   |
| RBBB                                   | 21 (3.2)     | 15 (2.9)   | 6 (4.5)     | 0.501   |
| **Management**                         |              |            |             |         |
| Chest pain nurse referral              | 36 (3.4)     | 5 (0.5)    | 31 (22.8)   | <0.001  |
| Cardiology referral                    | 50 (4.8)     | 14 (1.5)   | 36 (26.5)   | <0.001  |
| Admitted to hospital                   | 609 (58.2)   | 512 (56.2) | 97 (71.3)   | 0.001   |
| Echocardiogram                         | 17 (1.6)     | 5 (0.5)    | 12 (8.8)    | <0.001  |
| Coronary angiogram                     | 17 (1.6)     | 2 (0.2)    | 15 (11.0)   | <0.001  |
| PCI                                    | 10 (1.0)     | 0 (0.0)    | 10 (7.4)    | <0.001  |
| CABG                                   | 1 (0.1)      | 0 (0.0)    | 1 (0.7)     | 0.27    |
Supplementary Table 2 (Continued)

| Troponin requested by clinician | All (n=1,054) | No (n=918) | Yes (n=136) | P-value |
|--------------------------------|--------------|------------|-------------|---------|
| **Discharge drugs**           |              |            |             |         |
| Aspirin                        | 192 (18.8)   | 131 (14.7) | 61 (45.5)   | <0.001  |
| Clopidogrel                    | 102 (10.0)   | 69 (7.8)   | 33 (24.6)   | <0.001  |
| Beta-blockers                  | 152 (14.9)   | 106 (11.9) | 46 (34.3)   | <0.001  |
| ACEI/ARB                       | 181 (17.7)   | 134 (15.1) | 47 (35.1)   | <0.001  |
| Statin                         | 256 (25.0)   | 192 (21.5) | 64 (47.8)   | <0.001  |
| Warfarin                       | 44 (4.3)     | 33 (3.7)   | 11 (8.2)    | 0.03    |
| Proton pump inhibitor          | 246 (24.0)   | 193 (21.7) | 53 (39.6)   | <0.001  |

Values are n (%), mean ± SD or median [IQR].
Abbreviations: bpm=breaths/beats per minute; BP=blood pressure; PCI=percutaneous coronary intervention, CABG=coronary artery bypass grafting, ACE-I/ARB=angiotensin converting enzyme inhibitor/angiotensin receptor blocker, PPI=proton pump inhibitor.

*Consists of all patients with troponin levels above the 99th percentile upper reference limit using sex specific diagnostic thresholds including those further classified as type 1 and type 2 myocardial infarction.

Supplementary Table 3
Case Series of Patients Classified as Type 1 or Type 2 Myocardial Infarction in Whom the Attending Clinician Did Not Request Cardiac Troponin

| Age | Sex | Classification | Presenting complaint | Known IHD | TnI, ng/L | Ischemia on ECG | Admitted | Clinical details |
|-----|-----|----------------|----------------------|-----------|----------|-----------------|----------|------------------|
| 94  | M   | Type 1         | Chest pain           | No        | 1,377    | Yes             | Yes      | Late presentation myocardial infarction, not for escalation of care, died in hospital. |
| 44  | M   | Type 1         | Chest pain           | No        | 132      | No              | No       | Atypical history of chest pain. |
| 65  | M   | Type 2         | Breathlessness       | No        | 46       | Yes             | Yes      | Patient with multiple comorbidities and admitted with shortness of breath secondary to exacerbation of COPD. |
| 94  | F   | Type 2         | Chest pain           | No        | 24       | No              | Yes      | Admitted with fast ventricular response to atrial fibrillation and associated chest tightness. |
| 72  | M   | Type 2         | Chest pain           | No        | 36       | Yes             | Yes      | Admitted with fast ventricular response to atrial fibrillation and associated chest pain with rate related left bundle branch block. |

Supplementary Table 4
Presenting Complaint in Patients Without Suspected Acute Coronary Syndrome and Cardiac Troponin Concentrations >99th Centile

| Presenting complaint | Number (n = 114) | Percentage |
|----------------------|------------------|------------|
| Fall/Collapse        | 39               | 34.2%      |
| Chest pain           | 11               | 9.6%       |
| Dyspnea              | 10               | 8.8%       |
| Abdominal pain       | 8                | 7.0%       |
| Dizziness            | 4                | 3.5%       |
| Confusion            | 3                | 2.6%       |
| Other                | 39               | 34.2%      |

Supplementary Table 5
Primary Clinical Diagnostic Category of Patients with Cardiac Troponin Concentrations >99th Centile

| Diagnostic category | Number (n = 114) | Percentage |
|---------------------|------------------|------------|
| Infective / sepsis  | 31               | 27%        |
| Mechanical fall     | 15               | 13%        |
| Other               | 14               | 12%        |
| Cardiac*            | 12               | 11%        |
| Respiratory†        | 11               | 10%        |
| Trauma / Orthopaedic| 10               | 9%         |
| Gastroenterology / hepatology | 7 | 6% |
| Renal               | 6                | 5%         |
| Surgical            | 5                | 4%         |
| Neurological        | 3                | 3%         |

*In patients with a cardiac diagnosis, atrial fibrillation accounted for the majority (n=8).
†These refer to respiratory diagnoses other than pneumonia which was included within the Infective/sepsis category.
| Death category   | Number (n = 102) | Percentage |
|------------------|------------------|------------|
| Sepsis           | 20               | 19.6%      |
| Cancer           | 12               | 11.8%      |
| Respiratory      | 7                | 6.9%       |
| Gastrointestinal | 6                | 5.9%       |
| Cardiac          | 5                | 4.9%       |
| Stroke           | 3                | 2.9%       |
| Vascular         | 3                | 2.9%       |
| Renal            | 3                | 2.9%       |
| Other            | 3                | 2.9%       |
| Unknown          | 40               | 39.2%      |